Drug Type Tregs cell therapy |
Synonyms CD4+CD127lo/-CD25+ polyclonal Tregs, Regulatory T lymphocyte cell, CLBS 03 + [4] |
Target- |
Action modulators |
Mechanism Treg modulator |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 2 | United States | 01 Feb 2016 | |
Asthma | Preclinical | United States | - | |
Graft Rejection | Preclinical | United States | - | |
Multiple Sclerosis | Preclinical | United States | - | |
Systemic Lupus Erythematosus | Preclinical | United States | - |
Phase 2 | 113 | (CLBS03 Low Dose) | sduqxhfizg(xudhfgwmfs) = jszygoxsun zkuxlwnceh (ijyhmpxlap, 0.25988) View more | - | 08 Jan 2021 | ||
(CLBS03 High Dose) | sduqxhfizg(xudhfgwmfs) = elkjlolrba zkuxlwnceh (ijyhmpxlap, 0.31425) View more | ||||||
Phase 2 | 110 | ylmwjhieyx(kvhbudltxc) = no improve(vs. placebo) lbxhmrbodg (qhjcjbpktx ) View more | Negative | 13 Feb 2019 | |||
Placebo |